Cargando…

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy

INTRODUCTION: Various types of dermatological manifestations have been reported due to hepatitis C virus (HCV) infection and antiHCV therapy. Some of them have been described during IFN-based therapies. PEG-IFN-α-2a/RBV combination is used as the international standard of treatment for HCV infectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turker, Kamuran, Tas, Betul, Ozkaya, Murat, Tas, Ebru, Caglar, Aysel, Tetikkurt, Umit Seza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360537/ https://www.ncbi.nlm.nih.gov/pubmed/25821474 http://dx.doi.org/10.5812/hepatmon.24804

Ejemplares similares

Albendazole-induced anagen effluvium
por: Ghias, Mondana H., et al.
Publicado: (2019)

Anagenes statt telogenes Effluvium?
por: Gisy, Jenny
Publicado: (2022)

Tulipoid Hair: Anagen Effluvium Marker!
por: Malakar, Subrata S, et al.
Publicado: (2018)

Anagen Effluvium: A Trichoscopic Analysis
por: Gupta, Savera, et al.
Publicado: (2020)

Anagen Effluvium Following Acute Colchicine Poisoning
por: Combalia, Andrea, et al.
Publicado: (2016)

Anagen Effluvium after Methotrexate: An Idiosyncratic Reaction
por: Sinha, Preema, et al.
Publicado: (2020)

An Interesting Case Report of Azathioprine-Induced Anagen Effluvium
por: Balasubramanian, Pradeep, et al.
Publicado: (2015)

Azathioprine Induced Anagen Effluvium- An Uncommon Adverse Effect of a Commonly Used Drug
por: Sharma, Rashmi, et al.
Publicado: (2022)

A Comparative Study on the Rate of Anagen Effluvium and Survival Rates of Scalp, Beard, and Chest Hair in Hair Restoration Procedure of Scalp
por: Gupta, Jyoti, et al.
Publicado: (2019)

Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma
por: Tetikkurt, Seza, et al.
Publicado: (2018)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
por: Lim, Jae Hee, et al.
Publicado: (2011)

The psychologic impact of loose anagen syndrome and short anagen syndrome
por: Randolph, Michael J., et al.
Publicado: (2022)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

A rare cause of type 1 complex regional pain syndrome: Osteoblastoma of the talus
por: Beytemür, Ozan, et al.
Publicado: (2019)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium
por: Wambier, Carlos Gustavo, et al.
Publicado: (2022)

Localized Giant Cell Tenosynovial Tumor Seen in the Knee Joint
por: Beytemür, Ozan, et al.
Publicado: (2014)

Microcystic, elongated, and fragmented pattern of invasion in relation to histopathologic and clinical prognostic factors in endometrioid endometrial adenocarcinoma
por: Naki, M. Murat, et al.
Publicado: (2017)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Round atelectasis in sarcoidosis
por: Tetikkurt, Cuneyt, et al.
Publicado: (2011)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p61do7c2e43ec20jmdgp18tg28